Project Grant R21AI202414
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $194K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Glassboro, NJ 08028, USA
Similar Awards
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $474,363.00 to Rowan University to develop novel antimicrobial peptides inspired by the clinically approved compound daptomycin. The goal is to create new peptide molecules that mimic daptomycin's key mechanisms of action, such as calcium binding and lipid membrane disruption, while improving resistance to...
- The National Institute of Allergy and Infectious Diseases awarded Marshall University Research Corporation $221,250 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the functional redundancy and activation mechanisms of enterococcal proteases in catheter-associated urinary tract infections. The research addresses how secreted metalloproteases and serine proteases produced by Enterococcus faecalis enable biofilm formation and tissue invasion...
- The National Institute of Allergy and Infectious Diseases awarded the University of Miami $617,438 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a rapid cell-based diagnostic test for urinary tract infections and antimicrobial resistance screening. The project addresses the clinical need for point-of-care UTI diagnosis and antibiotic selection. Current diagnostic methods—urine analysis and culture—require 1–3 days for results and lack...
- The National Institute of Allergy and Infectious Diseases awarded Rutgers, The State University $421,889 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate cytosolic copper ion accumulation and proteome integrity in Staphylococcus aureus. The project addresses antimicrobial resistance in S. aureus and other ESKAPE pathogens by examining how copper ions toxify bacteria through protein misfolding and aggregation. The research characterizes...
- The National Institute of Allergy and Infectious Diseases awarded The University Corporation $147,500 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a multi-scale study of antimicrobial peptide action in non-standard bacterial growth states. The project addresses how antimicrobial peptides (AMPs)—immune-derived molecules that kill bacteria by disrupting membranes and modulate host immune responses—perform under physiologically relevant...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $571,412 to the University of Maryland, College Park on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the regulation of bacterial physiology and infections through linear diribonucleotides and RNA degradation. The project will characterize how diribonucleases and triribonucleases bind their respective...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $610,124 on February 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop BCG-mediated immunotherapy against recurrent bacterial bladder infections. The research addresses the annual cost of $3.5 billion spent in the U.S. to manage bladder infections and their recurrence, driven by the ability of uropathogenic E. coli to persist in the bladder and trigger reinfection...
- The National Institute of Allergy and Infectious Diseases awarded Purdue University $442,500 on September 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antimicrobial agents derived from aapeptide biomaterials targeting drug-resistant bacterial infections. The research addresses antimicrobial resistance identified by the World Health Organization as a major twenty-first-century threat. Purdue will develop small-molecule scorpion-like amphipathic...
- The National Institute of Allergy and Infectious Diseases awarded Catholic University of America $596,250 on May 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to prototype a rapid antibiotic susceptibility testing platform using multiplex static gradients. The project aims to develop a microfluidic device that identifies effective antibiotics within 30 minutes for acute bacterial infections such as sepsis, urinary tract infections, and bloodstream...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $684,405 on July 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop mucosal immunotherapies targeting recurrent urinary tract infections and inflammatory bowel disease. The funded research advances immunomodulation via self-assembled peptides (ISAP), a platform using modular supramolecular polypeptide nanomaterials designed to elicit neutralizing antibody responses against...